RESUMO
Introduction: Atmospheric contamination is closely linked to negative impacts on public health. Understanding the unique aspects of the Brazilian context is crucial for the implementation of public policies and health promotion. Objective: To assess the negative impacts of air pollution on public health in Brazil. Method: This review was developed through a search in the Latin American and Caribbean Health Sciences Information Literature (LILACS), Scientific Electronic Library Online (SciELO), and PubMed/Medline databases, using the keywords "Air Pollution" AND (Health OR "Public Health") AND "Adverse Effects" AND Brazil. Articles written in English and Portuguese, published from 2013 to 2024, were selected. Additionally, two articles were manually included. After applying the inclusion criteria and removing duplicates, 19 references were used for this review. Results and Discussion: There is a significant correlation between respiratory diseases and the emission of atmospheric pollutants, particularly the release of fine suspended particles (PM10), highlighting an increase in hospitalizations due to respiratory illnesses. The lack of studies addressing the effects of pollutants on other systems of the human body beyond the respiratory and cardiovascular systems, as well as the scarcity of information on various atmospheric pollutants, underscores the need for further research to fill these gaps. Conclusion: Even at levels considered acceptable, atmospheric pollutants still pose risks to public health. Therefore, specific public policies aimed at reducing emissions of these gasses and improving air quality are necessary.
RESUMO
Lung cancer is a highly aggressive neoplasm and, despite the development of recent therapies, tumor progression and recurrence following the initial response remains unsolved. Several questions remain unanswered about non-small cell lung cancer (NSCLC): (1) Which patients will actually benefit from therapy? (2) What are the predictive factors of response to MAbs and TKIs? (3) What are the best combination strategies with conventional treatments or new antineoplastic drugs? To answer these questions, an integrative literature review was carried out, searching articles in PUBMED, NCBI-PMC, Google Academic, and others. Here, we will examine the molecular genetics of lung cancer, emphasizing NSCLC, and delineate the primary categories of inhibitors based on their molecular targets, alongside the main treatment alternatives depending on the type of acquired resistance. We highlighted new therapies based on epigenetic information and a single-cell approach as a potential source of new biomarkers. The current and future of NSCLC management hinges upon genotyping correct prognostic markers, as well as on the evolution of precision medicine, which guarantees a tailored drug combination with precise targeting.
